Embecta

Embecta Receivables/Revenue

The Receivables to Revenue Ratio of Embecta (EMBC) as of Oct 22, 2026 is 13.48 %. In the previous year, Receivables to Revenue Ratio was 17.29 % — a change of -22.06% (lower).

Receivables/Revenue

13.48 %

YoY

-22.06%

Last updated:

Receivables to Revenue Ratio of Embecta is 2025 13.48 % . Receivables to Revenue Ratio of Embecta was 2024 17.29 % . It decreases by -22.06% lower compared to the previous year.

The Embecta Receivables/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables/Revenue
Date
Receivables/Revenue
Jan 1, 2019
10.64 USD
Jan 1, 2020
11.05 USD
Jan 1, 2021
12.96 USD
Jan 1, 2022
2.07 USD
Jan 1, 2023
1.60 USD
Jan 1, 2024
17.29 USD
Jan 1, 2025
13.48 USD
The Embecta Receivables/Revenue history
YEARReceivables/RevenueYoY
13.48 %-22.06%
17.29 %+982.69%
1.60 %-22.91%
2.07 %-84.02%
12.96 %+17.25%
11.05 %+3.90%
10.64 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Embecta Stock analysis

What does Embecta do? Embecta Corp. generates revenue through the manufacturing and distribution of medical devices for diabetes treatment, including pen needles, syringes, and safety injection devices. Its product portfolio features sterile, single-use pen needles designed for use with insulin pens, safety pen needles with dual-end shields to prevent needlestick injuries, and sterile insulin syringes for drawing insulin from vials. The company sells these products through retail, hospital, pharmacy, and institutional channels to customers managing diabetes. The firm’s digital application, integrated with its physical products, supports diabetes management by assisting users in tracking and administering insulin. This complementary digital solution enhances the value of its device offerings, attracting both individual consumers and healthcare institutions seeking comprehensive diabetes care solutions. Embecta Corp. focuses on providing end-to-end solutions for people living with diabetes, leveraging its product range and digital tools to address key challenges in diabetes management. Embecta is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Embecta stock

Receivables to Revenue Ratio of Embecta is 13.48 % in 2025.

Receivables to Revenue Ratio of Embecta changed from 17.29 % to 13.48 %, representing a -22.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Receivables to Revenue Ratio Embecta since 2006 – with annual values, charts, and detailed analysis.

The Receivables/Revenue ratio shows what percentage of annual revenue is tied up in accounts receivable. Rising ratios may signal collection issues.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Receivables to Revenue Ratio's Embecta with sector peers and the industry average to assess whether it is attractive.

To evaluate Receivables to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Receivables to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Embecta

All Key Metrics — Embecta